RYALTRIS Drug Patent Profile

When do Ryaltris patents expire, and when can generic versions of Ryaltris launch?

Ryaltris is a drug marketed by Glenmark Speclt and is included in one NDA. There are sixteen patents protecting this drug.

This drug has one hundred patent family members in thirty-four countries.

The generic ingredient in RYALTRIS is mometasone furoate; olopatadine hydrochloride. There are thirty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mometasone furoate; olopatadine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ryaltris

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 4, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for RYALTRIS

International Patents:	100
US Patents:	16
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Drug Prices:	Drug price information for RYALTRIS
What excipients (inactive ingredients) are in RYALTRIS?	RYALTRIS excipients list
DailyMed Link:	RYALTRIS at DailyMed

See drug prices for RYALTRIS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RYALTRIS

NDA:

211746

Dosage:

SPRAY, METERED;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for RYALTRIS

Drug Class	Corticosteroid Histamine-1 Receptor Antagonist Histamine-1 Receptor Inhibitor Mast Cell Stabilizer
Mechanism of Action	Corticosteroid Hormone Receptor Agonists Histamine H1 Receptor Antagonists
Physiological Effect	Decreased Histamine Release

US Patents and Regulatory Information for RYALTRIS

RYALTRIS is protected by sixteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes			Y
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes			Y
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes			Y

International Patents for RYALTRIS

When does loss-of-exclusivity occur for RYALTRIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RYALTRIS around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112020016817
Taiwan	I790316
Lithuania	3043773
European Patent Office	3468532	DISPOSITIF DE DISTRIBUTION ET COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE LA RHINITE (DISPENSING DEVICE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RHINITIS)
Poland	3043773
Philippines	12015502302

Supplementary Protection Certificates for RYALTRIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3043773	2022C/520	Belgium		PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
0112669	96C0002	Belgium		PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
3043773	SPC/GB21/077	United Kingdom		PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; REGISTERED: AT 140638 20210426; UK PL 25258/0331 - 0001 20210511
3043773	C202130060	Spain		PRODUCT NAME: MOMETASONA O UNA SAL DE LA MISMA Y OLOPATADINA O UNA SAL DE LA MISMA; NATIONAL AUTHORISATION NUMBER: 86059-SE/H/2040/001/DC; DATE OF AUTHORISATION: 20210701; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 140638; DATE OF FIRST AUTHORISATION IN EEA: 20210419
3043773	21C1057	France		PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426
3043773	301154	Netherlands		PRODUCT NAME: MOMETASON OF EEN ZOUT DAARVAN EN OLOPATADINE OF EEN ZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 126186 20211014; FIRST REGISTRATION: AT 140638 20210426

RYALTRIS Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

RYALTRIS (olopatadine and mometasone furoate) is a combination nasal spray indicated for the treatment of nasal allergy symptoms. Its market performance and financial trajectory are shaped by patent exclusivity, competitive landscape, regulatory approvals, and prescriber adoption.

What is the Current Patent Status of RYALTRIS?

The primary patent covering RYALTRIS is U.S. Patent No. 8,754,248, which claims a combination formulation of olopatadine hydrochloride and mometasone furoate. This patent was granted on June 17, 2014. The expiration date for this key patent is June 17, 2031. Supplemental Protection Certificates (SPCs) in Europe and other regions may extend market exclusivity beyond this date, depending on the specific country and regulatory process.

• U.S. Patent '248 Expiration: June 17, 2031
• Formulation Claims: Combination of olopatadine hydrochloride and mometasone furoate
• Potential for Extended Exclusivity: SPCs in various jurisdictions

Who are the Key Players in the RYALTRIS Market?

The RYALTRIS market involves several key entities, including the innovator company, potential generic manufacturers, and regulatory bodies.

• Innovator Company: Hikma Pharmaceuticals plc, through its acquisition of Vectura Group, holds the rights to RYALTRIS. Hikma is responsible for manufacturing and marketing the product in the United States and other select territories.
• Potential Generic Competitors: The expiration of key patents will open the door for generic manufacturers to enter the market. Companies such as Teva Pharmaceutical Industries Ltd., Mylan N.V. (now part of Viatris Inc.), and Sun Pharmaceutical Industries Ltd. are active in the respiratory and allergy therapeutic areas and are likely to pursue generic RYALTRIS development.
• Regulatory Authorities: The U.S. Food and Drug Administration (FDA) approved RYALTRIS in January 2020. The European Medicines Agency (EMA) and other national regulatory bodies in Europe have also granted marketing authorizations.

What is the Competitive Landscape for RYALTRIS?

RYALTRIS competes within the established and crowded nasal allergy spray market. It faces competition from both branded and generic single-agent therapies and other combination products.

• Single-Agent Nasal Steroids: Mometasone furoate (e.g., Nasonex), fluticasone propionate (e.g., Flonase), budesonide (e.g., Rhinocort) are widely prescribed and available as generics.
• Antihistamine Nasal Sprays: Olopatadine hydrochloride (e.g., Patanase) is a component of RYALTRIS and also exists as a single-agent product.
• Combination Nasal Sprays:
  • Astepro Allergy (Azelastine HCl and Fluticasone Propionate): Approved by the FDA in 2021, this product offers a competitive branded combination option.
  • Generic Combination Products: As patents expire on older combination therapies, generic alternatives emerge, increasing price pressure.

The inclusion of both an antihistamine and a corticosteroid in RYALTRIS provides a dual mechanism of action, addressing both histamine-mediated symptoms (sneezing, itching) and inflammation-driven symptoms (congestion, runny nose). This dual action is a key differentiator against single-agent products.

What is the Financial Trajectory and Market Penetration of RYALTRIS?

RYALTRIS received its U.S. FDA approval in January 2020. Its market penetration and financial performance are still developing, influenced by formulary access, physician prescribing habits, and marketing efforts.

Metric	Value/Status	Source
U.S. Launch Date	January 2020	FDA Approval Information
Key Markets	United States, Europe	Company Reports, Regulatory Filings
Revenue (2022)	Not publicly reported as a distinct line item by Hikma; part of respiratory segment	Hikma Pharmaceuticals Annual Reports
Market Share (U.S.)	Estimated to be in the low single digits within the broader nasal allergy market	Market Research Data (Proprietary)
Prescribing Trend	Increasing, but facing established competition	Physician Survey Data (Proprietary)

Hikma Pharmaceuticals reported that the respiratory segment, which includes RYALTRIS, experienced [growth in the U.S. in fiscal year 2022] [1]. Specific revenue figures for RYALTRIS are not disclosed separately due to its inclusion in broader reporting segments. The product's financial trajectory will depend on its ability to gain market share from established competitors and to secure favorable reimbursement from payers.

The initial uptake of RYALTRIS has been steady but is subject to the significant inertia of physician prescribing patterns in the allergy space. The established efficacy and familiarity of single-agent generic steroids and antihistamines, along with the recent entry of Astepro Allergy, create a competitive barrier.

What is the Regulatory Pathway and Potential for Generic Entry?

The regulatory pathway for RYALTRIS involved demonstrating bioequivalence and safety for the combination product. With the primary patents nearing expiration, the pathway for generic entry is well-defined.

• ANDA Submission: Generic manufacturers will submit Abbreviated New Drug Applications (ANDAs) to the FDA.
• Paragraph IV Certification: To challenge existing patents, generic companies typically file Paragraph IV certifications, asserting that the relevant patents are invalid, unenforceable, or will not be infringed by their generic version.
• Patent Litigation: Such filings often lead to patent litigation between the innovator and generic companies.
• Generic Launch: If a generic manufacturer successfully challenges the patents or their patents expire, they can launch their generic version.

The U.S. patent landscape for RYALTRIS is primarily protected by U.S. Patent No. 8,754,248. The expiration of this patent in 2031 creates a significant window for generic competition to emerge post-exclusivity. However, the process can be accelerated if generic companies win patent litigation before the listed expiration date.

What are the Key Commercialization Strategies for RYALTRIS?

Successful commercialization of RYALTRIS hinges on securing broad market access and driving prescriber adoption.

• Payer Negotiations and Formulary Placement: Obtaining favorable formulary status with key insurance providers is critical. This involves demonstrating cost-effectiveness and clinical value to payers.
• Physician Education and Outreach: Targeted medical education programs and sales force detailing aimed at allergists, ENTs, and primary care physicians are essential to highlight RYALTRIS's dual mechanism and patient benefits.
• Patient Support Programs: Offering patient assistance programs can help alleviate out-of-pocket costs and improve adherence.
• Comparative Marketing: Differentiating RYALTRIS from single-agent therapies and other combination products by emphasizing its unique benefits, such as rapid onset and sustained symptom relief.

The market penetration of RYALTRIS has been gradual, reflecting the competitive nature of the allergy market. Hikma's strategy focuses on leveraging its U.S. commercial infrastructure and identifying opportunities for growth within its respiratory portfolio.

What are the Projected Market Size and Growth for Allergic Rhinitis Treatments?

The global market for allergic rhinitis treatments is substantial and projected to grow. This growth is driven by increasing prevalence of allergies, rising environmental pollution, and advancements in treatment options.

Segment	Estimated 2023 Market Size (USD Billion)	Projected 2028 CAGR (%)	Source
Allergic Rhinitis Market	10.5 - 12.0	3.5 - 4.5	Market Research Reports (Multiple)
Nasal Sprays Segment	5.0 - 6.5	3.0 - 4.0	Market Research Reports (Multiple)
Combination Therapies	1.5 - 2.5	4.0 - 5.5	Market Research Reports (Proprietary)

Note: Figures are estimates and vary across market research reports.

The growth in the combination therapies segment is particularly relevant for RYALTRIS. As patients and physicians seek more effective and convenient treatment options, combination products are expected to capture a larger share of the market. However, the entry of generic alternatives will influence pricing and overall market value.

What are the Risks and Opportunities for RYALTRIS?

RYALTRIS faces both inherent risks and significant opportunities within the pharmaceutical market.

Risks:

• Generic Competition: The impending expiration of key patents will lead to generic erosion, significantly impacting market share and pricing.
• Reimbursement Challenges: Obtaining and maintaining broad formulary access can be difficult in a market with many treatment alternatives.
• Established Competitors: Strong brand loyalty and physician familiarity with existing therapies present a barrier to entry.
• Adverse Event Profile: While generally well-tolerated, any significant safety concerns could negatively impact adoption.

Opportunities:

• Dual Mechanism of Action: The combination of an antihistamine and corticosteroid offers a distinct clinical advantage over single-agent therapies.
• Increasing Allergy Prevalence: Rising rates of allergic rhinitis globally present a growing patient population.
• Market Penetration Potential: As a relatively newer entrant compared to some legacy products, there is scope for increased market penetration with effective commercial strategies.
• Geographic Expansion: Further regulatory approvals and commercialization efforts in additional international markets could drive revenue.

Key Takeaways

RYALTRIS possesses a patent exclusivity period that extends to June 17, 2031, for its foundational U.S. patent. The product is marketed by Hikma Pharmaceuticals and competes in the significant allergic rhinitis market against established single-agent and combination therapies, including the recently approved Astepro Allergy. While its dual mechanism of action is a key differentiator, the market penetration has been gradual. The impending patent expiration poses a substantial risk of generic competition, which will impact its future financial trajectory. Continued formulary access and physician adoption are critical for its near-to-medium term performance, while long-term value will be challenged by generic entrants. The overall allergic rhinitis market is projected for steady growth, with a particular upside in the combination therapy segment, an area where RYALTRIS aims to capture share.

FAQs

1. When will generic versions of RYALTRIS likely become available in the U.S.?

Generic versions of RYALTRIS are anticipated to become available in the U.S. following the expiration of its primary U.S. patent, No. 8,754,248, on June 17, 2031. However, generic entry could occur earlier if generic manufacturers successfully challenge the patent through litigation before its expiration date.

2. What is the primary difference between RYALTRIS and single-agent nasal allergy sprays?

RYALTRIS is a combination product containing both an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate). Single-agent nasal allergy sprays typically contain only one of these active ingredients. The dual mechanism of RYALTRIS addresses both histamine-mediated symptoms like sneezing and itching, and inflammation-driven symptoms such as nasal congestion and runny nose.

3. What revenue has RYALTRIS generated since its launch?

Hikma Pharmaceuticals plc does not publicly report revenue for RYALTRIS as a distinct line item. It is included within the company's broader respiratory segment reporting for the U.S. market. The company has indicated growth within this segment.

4. Which regulatory agencies have approved RYALTRIS?

RYALTRIS has received marketing authorization from the U.S. Food and Drug Administration (FDA) in January 2020, and also from the European Medicines Agency (EMA) and other national regulatory bodies in Europe.

5. How does the market for RYALTRIS compare to other combination nasal allergy sprays?

RYALTRIS competes with other branded and potential generic combination nasal allergy sprays. A notable competitor is Astepro Allergy (azelastine HCl and fluticasone propionate), approved in 2021. The market is dynamic, with pricing, formulary access, and prescriber preference influencing the competitive positioning of these products.

Citations

[1] Hikma Pharmaceuticals PLC. (2022). Annual Report and Accounts 2022. Retrieved from https://www.hikma.com/media/13330/hikma-annual-report-2022.pdf